A Phase 2, open-label, placebo-controlled trial of topical itraconazole 0.7% gel applied for 1–3 months in BCC treatment did not yield reduction of GLI1 mRNA expression or tumor size [126]. The gene discussed is GLI1; the disease is skin basal cell carcinoma.